Enovis Corporation (NYSE:ENOV) Receives Average Recommendation of “Moderate Buy” from Brokerages

Enovis Corporation (NYSE:ENOV) has earned an average recommendation of “Moderate Buy” from the eight research firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $47.4286.

A number of equities analysts recently weighed in on the company. BTIG Research raised their price objective on Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a report on Thursday. Needham & Company LLC raised their price objective on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday. Canaccord Genuity Group decreased their price objective on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, December 17th. Wells Fargo & Company raised their target price on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, UBS Group restated a “buy” rating and set a $50.00 price target on shares of Enovis in a report on Monday, January 5th.

Insider Activity at Enovis

In other Enovis news, EVP Daniel A. Pryor sold 999 shares of the business’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $27.20, for a total value of $27,172.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.70% of the company’s stock.

Institutional Trading of Enovis

A number of hedge funds have recently modified their holdings of ENOV. Arax Advisory Partners acquired a new stake in Enovis during the 4th quarter worth $29,000. Farther Finance Advisors LLC raised its stake in shares of Enovis by 42.8% in the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock valued at $37,000 after acquiring an additional 367 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares in the last quarter. Elevation Point Wealth Partners LLC purchased a new position in shares of Enovis in the 2nd quarter valued at about $46,000. Finally, SJS Investment Consulting Inc. boosted its stake in Enovis by 30,340.0% in the third quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock valued at $46,000 after acquiring an additional 1,517 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Stock Performance

Shares of ENOV stock opened at $25.49 on Tuesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.16 and a current ratio of 2.22. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -1.23 and a beta of 1.52. The firm’s 50-day simple moving average is $24.27 and its two-hundred day simple moving average is $28.19. Enovis has a 52 week low of $21.00 and a 52 week high of $40.69.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 7.91%. The firm had revenue of $575.76 million for the quarter, compared to the consensus estimate of $584.30 million. During the same period in the prior year, the firm posted $0.98 earnings per share. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities analysts forecast that Enovis will post 2.79 earnings per share for the current year.

Trending Headlines about Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Adjusted EPS beat — Enovis reported adjusted EPS $0.95 versus consensus ~$0.81, signaling underlying profitability on a non‑GAAP basis. Enovis Q4 2025 Earnings Call Highlights
• Positive Sentiment: Management raised FY2026 adjusted EPS guidance to $3.52–$3.73 (above consensus ~3.35) and expects adjusted EBITDA expansion, providing a clearer path to earnings recovery. Enovis targets $2.31–$2.37B 2026 revenue
• Positive Sentiment: Operational momentum — full‑year 2025 net sales grew ~7% (6% organic) with Reconstructive up ~10% Y/Y; adjusted EBITDA and adjusted EPS for the year improved on a non‑GAAP basis. Enovis Announces Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Analyst activity supportive — BTIG raised its price target to $43 and keeps a buy stance, signaling some sell‑side confidence in the recovery story. BTIG price target raise
• Neutral Sentiment: Guidance mix — revenue guidance of $2.31–$2.37B implies 4–6% organic growth (positive), but the top‑end sits below some street expectations — a watch item for revenue‑sensitive investors. Guidance detail
• Negative Sentiment: Revenue miss and GAAP impairment — Q4 revenue ~$575.8M missed consensus (~$584M) and the company took a $501M non‑cash goodwill impairment (Q4) that produced a large GAAP loss (Q4 net loss from continuing operations ~$519M), raising concerns about past acquisition valuation and near‑term GAAP volatility. Enovis Misses Q4 Sales Expectations
• Negative Sentiment: Significant non‑cash charges dent headline results — investors focused on GAAP losses and goodwill write‑downs may remain cautious despite positive adjusted metrics. Quiver/summary of results and impairment

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.